Media

Follow our progress and stay up to date with our press releases and media coverage.

Press Releases

GeneVentiv Therapeutics Expands Scientific Advisory Board

GeneVentiv Therapeutics Expands Scientific Advisory Board

March 3, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective, and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the expansion of...

read more
Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia

Geneventiv Therapeutics Licenses Gene Therapy for Hemophilia

GeneVentiv Therapeutics and University of North Carolina Chapel Hill Enter License Agreement RALEIGH, NC, November 2, 2020 — GeneVentiv Therapeutics, Inc. has entered into a license agreement with the University of North Carolina Chapel Hill for a patent pending, gene...

read more

In the News

UNC-Chapel Hill gene therapy spinout raises $1.4 million

UNC-Chapel Hill gene therapy spinout raises $1.4 million

By Zac Ezzone  –  Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...

read more
Bootstrapped UNC spinout lands $300K for gene therapy work

Bootstrapped UNC spinout lands $300K for gene therapy work

The Old Well on the UNC-Chapel Hill campus. Mehmet Demirci By Zac Ezzone - Staff writer June 14, 2022, 08:52am EDT After bootstrapping for nearly two years, the CEO of a UNC-Chapel Hill spinout developing gene therapies has received some financial support. In March,...

read more
Universal hope for hemophilia

Universal hope for hemophilia

Universal hope for hemophilia Current hemophilia treatments have limitations for a significant number of patients. That’s why UNC-connected startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia,...

read more
Potential Gene Therapy GENV-HEM Earns Orphan Drug Status

Potential Gene Therapy GENV-HEM Earns Orphan Drug Status

Hemophilia News Today by Marta Figueiredo PhD | November 3, 2021 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without...

read more